Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rallybio (RLYB)
NASDAQ:RLYB
Rallybio (RLYB) Stock Price & Analysis
228 Followers
RLYB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.16 - $6.33
Previous Close$1.34
Volume48.44K
Average Volume (3M)252.76K
Market Cap
$55.54M
Enterprise Value-$38.29M
Total Cash (Recent Filing)$94.17M
Total Debt (Recent Filing)$339.00K
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Aug 06, 2024EPS Estimate
-$0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.88
Shares Outstanding41,449,297
10 Day Avg. Volume173,622
30 Day Avg. Volume252,760
Standard Deviation0.31
R-Squared0.08
Alpha-0.00700
Financial Highlights & Ratios
Price to Book (P/B)0.57
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.64
Forecast
1Y Price Target
$12.33Price Target Upside820.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Rallybio News
PremiumCompany Announcements
Rallybio Strengthens Ties with J&J in FNAIT Treatment Push
Bulls Say, Bears Say
Bulls Say
CollaborationsJNJ collaboration validates the FNAIT program, potentially leading to additional collaborations down the road.
Financial StabilityRallybio ended 1Q24 with roughly $94.2M in cash and equivalents, which the company expects to provide an operational runway into mid-2026.
Market OpportunityThe large-scale epidemiological analysis estimates over 30,000 pregnancies each year in the U.S. and EU are at risk for FNAIT, which exceeds prior reports and earlier estimates.
Bears Say
Clinical StudiesClinical studies for C5 inhibitor RLYB116 are paused pending additional funding and manufacturing improvements.
Financial PerformanceRLYB reported 1Q24 net loss of $19M ($0.47).
Workforce ReductionG&A was $6.9M, +32% Q/Q primarily related to severance costs incurred in connection with the 45% workforce reduction announced in Feb, completed in 1Q24.
---
Ownership Overview
62.79%
Insiders
6.13% Mutual Funds
7.13% Other Institutional Investors
23.95% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
RLYB FAQ
What was Rallybio’s price range in the past 12 months?
Rallybio lowest stock price was $1.16 and its highest was $6.33 in the past 12 months.
What is Rallybio’s market cap?
Currently, no data Available
When is Rallybio’s upcoming earnings report date?
Rallybio’s upcoming earnings report date is Aug 06, 2024 which is in 15 days.
How were Rallybio’s earnings last quarter?
Rallybio released its earnings results on May 09, 2024. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.473 by $0.003.
Is Rallybio overvalued?
According to Wall Street analysts Rallybio’s price is currently Undervalued.
Does Rallybio pay dividends?
Rallybio does not currently pay dividends.
What is Rallybio’s EPS estimate?
Rallybio’s EPS estimate is -$0.37.
How many shares outstanding does Rallybio have?
Rallybio has 41,449,300 shares outstanding.
What happened to Rallybio’s price movement after its last earnings report?
Rallybio reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.473. Following the earnings report the stock price went up 2.703%.
Which hedge fund is a major shareholder of Rallybio?
Among the largest hedge funds holding Rallybio’s share is Viking Global Investors LP. It holds Rallybio’s shares valued at 8M.
---
Rallybio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.33 (820.15% Upside)
$12.33 (820.15% Upside)
Blogger Sentiment
Neutral
RLYB Sentiment 50%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.47%
12-Months-Change
Fundamentals
Return on Equity
-62.43%
Trailing 12-Months
Asset Growth
-38.79%
Trailing 12-Months
Company Description
Rallybio
Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
---
RLYB Stock 12 Month Forecast
Average Price Target
$12.33
▲(820.15% Upside)
Technical Analysis
Best Analysts Covering RLYB
1 Year
1 Year Success Rate
1/25 ratings generated profit
1 Year Average Return
-48.08%
reiterated a buy rating last month
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 4.00% of your transactions generating a profit, with an average return of -48.08% per trade.
---